Investor Relations

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

Stock Market
NASDAQSNGX
Featured Presentation

2020 Corporate Presentation 

Download

Interview with Soligenix Chief Medical Officer, Dr. Richard Straube, Regarding the Upcoming Phase 3 CTCL Data Readout

Read the Transcript

 

Latest News
Feb 13, 2020
FDA Grants Soligenix "Fast Track" Designation for RiVax® in the Prevention of Ricin Poisoning

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...

Feb 11, 2020
Soligenix Announces SGX301 Patient Case Study Presentation at the 4th World Congress of Cutaneous Lymphomas

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...

Feb 3, 2020
Soligenix Announces Japanese Patent Allowance for Use of Dusquetide in Oral Mucositis

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...

All Press Releases

IR Contacts

29 Emmons Drive
Suite B-10 Princeton, NJ 08540
Telephone: 609-538-8200
ir@soligenix.com

Subscribe For Alerts

If you would like to receive our Investor Relations updates, please sign up for email alerts. 

 

 

Sign Up